{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:16Z","timestamp":1785491896733,"version":"3.56.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pemphigus foliaceus (PF), a rare autoimmune blistering disease, still lacks a well-established optimal treatment approach. Rituximab (RTX) is not yet approved by the US Food and Drug Administration for the treatment of PF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and tolerability of RTX in treating PF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, all patients diagnosed with PF and treated with RTX and referred to a tertiary hospital over a period of 7 years were included. Clinical outcomes were retrospectively evaluated using Pemphigus Disease Area Index (PDAI) scores and prednisolone dosages at a minimum of four follow-up points. Patients were divided into two groups: newly diagnosed (NDP) and previously treated patients (PTP). Comparative analyses were performed across follow-up visits and study groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 96 patients were included. Significant decreases in PDAI scores and prednisolone dosages were observed for all patients (both P &amp;lt; 0.0001), with no significant differences found between the study groups during a 12-month follow-up period. The NDP group exhibited a higher rate of complete remission (P = 0.03) and a shorter time to complete remission (P = 0.006) compared with the PTP group. There were no significant variations in relapse rate and time to relapse among the study groups. The most common treatment-related adverse effects of RTX were those associated with the injection, which could be managed with supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RTX emerges as a promising therapeutic option with minimal side effects for the treatment of PF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag025","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:54:34Z","timestamp":1772283274000},"page":"446-453","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and tolerability of rituximab in patients with pemphigus foliaceus: a single-centre retrospective cohort study"],"prefix":"10.1093","volume":"6","author":[{"given":"Ali","family":"Sadeghinia","sequence":"first","affiliation":[{"name":"Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Tavasoli","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-1432","authenticated-orcid":false,"given":"Ahmad","family":"Vafaeian","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Naser","family":"Emadi","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Aryanian","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-8895","authenticated-orcid":false,"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[{"name":"Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026073105075582000_vzag025-B1","first-page":"1302","article-title":"Transition between pemphigus vulgaris and pemphigus foliaceus: a 10-year follow-up study","volume":"18","author":"Mohammadrezaee","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026073105075582000_vzag025-B2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/jid.2011.390","article-title":"Desmoglein as a target in skin disease and beyond","volume":"132","author":"Amagai","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2026073105075582000_vzag025-B3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3892\/etm.2021.10770","article-title":"Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (review)","volume":"22","author":"Costan","year":"2021","journal-title":"Exp Ther Med"},{"key":"2026073105075582000_vzag025-B4","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/ced.14041","article-title":"Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management","volume":"44","author":"Melchionda","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"2026073105075582000_vzag025-B5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.16883","article-title":"Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus","volume":"180","author":"Tamasi","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026073105075582000_vzag025-B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis & clinical features of pemphigus foliaceus","volume":"29","author":"James","year":"2011","journal-title":"Dermatol Clin"},{"key":"2026073105075582000_vzag025-B7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1525-1470.2007.00369.x","article-title":"Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment","volume":"24","author":"Connelly","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"2026073105075582000_vzag025-B8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B9","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105075582000_vzag025-B10","doi-asserted-by":"crossref","first-page":"e13016","DOI":"10.1111\/dth.13016","article-title":"Iranian guideline for rituximab therapy in pemphigus patients","volume":"32","author":"Daneshpazhooh","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026073105075582000_vzag025-B11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: a review in pemphigus vulgaris","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026073105075582000_vzag025-B12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/medicina57101080","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2026073105075582000_vzag025-B13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/09546634.2019.1617831","article-title":"Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study","volume":"32","author":"Toosi","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2026073105075582000_vzag025-B14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamadermatol.2024.6654","article-title":"Long-term efficacy and safety of rituximab in patients with pemphigus foliaceus compared with pemphigus vulgaris","volume":"161","author":"Tedbirt","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026073105075582000_vzag025-B15","doi-asserted-by":"crossref","first-page":"7318","DOI":"10.3390\/jcm14207318","article-title":"Eight years of follow-up of rituximab in pemphigus vulgaris and foliaceus at a single center: assessing efficacy and safety in light of several factors","volume":"14","author":"Szymanski","year":"2025","journal-title":"J Clin Med"},{"key":"2026073105075582000_vzag025-B16","doi-asserted-by":"crossref","first-page":"1267668","DOI":"10.3389\/fimmu.2023.1267668","article-title":"Current biologics in treatment of pemphigus foliaceus: a systematic review","volume":"14","author":"Carver","year":"2023","journal-title":"Front Immunol"},{"key":"2026073105075582000_vzag025-B17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000508788","article-title":"Treatment of pemphigus vulgaris and foliaceus with adjuvant rituximab compared to immunosuppression alone: real-life experience","volume":"237","author":"Snast","year":"2021","journal-title":"Dermatology"},{"key":"2026073105075582000_vzag025-B18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaad.2007.05.024","article-title":"Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris","volume":"57","author":"Chams-Davatchi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B20","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026073105075582000_vzag025-B21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","article-title":"A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus","volume":"64","author":"Martin","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1468-3083.2012.04717.x","article-title":"Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris","volume":"27","author":"Chams-Davatchi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105075582000_vzag025-B23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jaad.2014.03.020","article-title":"Opportunistic infections in patients with pemphigus","volume":"71","author":"Leshem","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","article-title":"The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis","volume":"73","author":"Atzmony","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B25","doi-asserted-by":"crossref","first-page":"e12827","DOI":"10.1111\/dth.12827","article-title":"\u201cChange over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran\u201d: a multiple cross-sectional study","volume":"32","author":"Salarvand","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026073105075582000_vzag025-B26","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2026073105075582000_vzag025-B27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","volume":"150","author":"Rahbar","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2026073105075582000_vzag025-B28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"2026073105075582000_vzag025-B29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/08923973.2021.1953063","article-title":"A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of pemphigus: special focus on COVID-19 pandemic concerns","volume":"43","author":"Tavakolpour","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2026073105075582000_vzag025-B30","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"2026073105075582000_vzag025-B31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2018.05.1252","article-title":"Rituximab treatment of pemphigus foliaceus: a retrospective study of 12 patients","volume":"85","author":"Palacios-\u00c1lvarez","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000513515","article-title":"Treatment of pemphigus with rituximab: real-life experience in a cohort of 117 patients in Israel","volume":"237","author":"Nosrati","year":"2021","journal-title":"Dermatology"},{"key":"2026073105075582000_vzag025-B33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026073105075582000_vzag025-B34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/bjd.13586","article-title":"Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature","volume":"172","author":"de Sena Nogueira Maehara","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026073105075582000_vzag025-B35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026073105075582000_vzag025-B36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00403-018-1881-1","article-title":"Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?","volume":"311","author":"Balighi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"2026073105075582000_vzag025-B37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijwd.2019.05.008","article-title":"Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naive and previously treated patients with pemphigus vulgaris after receiving rituximab","volume":"5","author":"Alaeen","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"2026073105075582000_vzag025-B38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt-2017-0104","article-title":"Rituximab in pemphigus","volume":"10","author":"Hebert","year":"2018","journal-title":"Immunotherapy"},{"key":"2026073105075582000_vzag025-B39","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"2026073105075582000_vzag025-B40","doi-asserted-by":"crossref","first-page":"e15264","DOI":"10.1111\/dth.15264","article-title":"A review of reported infectious events following rituximab therapy in pemphigus patients","volume":"35","author":"Shahrigharahkoshan","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026073105075582000_vzag025-B41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/446\/68187494\/vzag025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/446\/68187494\/vzag025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:08:10Z","timestamp":1785488890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/446\/8664928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag025","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,4,29]]}}}